Regen BioPharma, Inc.

  • Home
  • About Us
    • Management Team and Scientific Advisory Board
    • Careers
    • Contact Us
  • Products
  • Investor Relations
    • Regulatory Filings
  • Company News
  • Home
  • About Us
    • Management Team and Scientific Advisory Board
    • Careers
    • Contact Us
  • Products
  • Investor Relations
    • Regulatory Filings
  • Company News
Picture

Fast Forwarding Checkpoint Medicine
Striving to improve the quality of life by introducing the latest in medical technology for treating cancer and autoimmunity

Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP)  focused on the immunology and immunotherapy space. The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6.  The company also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).

Picture

Product Pipeline

Regen BioPharma is a biotechnology  company focused on stem cell and immunotherapies for specialty niche treatments.
​
Currently we are focused on aplastic anemia, gene silencing and small molecule development.
Complete listing, click
"READ MORE".




​
​
Read More
Picture

Investors

December 15, 2015 SOURCE: REGEN BIOPHARMA INC.  Regen BioPharma, Inc. Receives FDA Clearance to Initiate Clinical Trial of HemaXellerate. Company to initiate Phase I Clinical Trial for IMmune Modulatory Personalized Cell Therapy in Treatment of Aplastic Anemia.
READ MORE>>>

​Investor resources

Regen BioPharma Inc. trades under the symbol RGBP on the OTC Bulletin Board and OTC PINK markets. Regen is a biotechnology company focused on...
​
Read More
Picture

Company News

News and press releases listed by year for reading and downloading.








​
​


Read More

Regen BioPharma

About Us
Products
News
Management Team
Investor Relations
​Contact Us
© COPYRIGHT 2022. ALL RIGHTS RESERVED.

 Company Overview

Picture
• Founded in 2012 as a biotechnology company focused on stem cell and immunotherapies for specialty niche treatments.
• Fully reporting and trades publicly under the symbol: RGBP
• Focused on immuno-oncology, stem cell/cancer stem cell, gene silencing
• Currently 2 Investigational New Drug applications (IND) filed with the FDA
• Three products in preclinical development based on the newly discovered cancer stem cell gene target